<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451515</url>
  </required_header>
  <id_info>
    <org_study_id>NHL16</org_study_id>
    <secondary_id>NCI-2012-00496</secondary_id>
    <nct_id>NCT01451515</nct_id>
  </id_info>
  <brief_title>NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma</brief_title>
  <official_title>NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II clinical trial using risk-adapted therapy. The treatment is acute
      lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of
      induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months.
      Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral
      blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone
      marrow/peripheral blood lymphoma cells involvement at diagnosis for B-lymphoblastic lymphoma.

      The Primary Objective of this study is:

      To improve the outcome of children with lymphoblastic lymphoma (LL) who have minimal
      disseminated disease (MDD) equal to or more than 1% at diagnosis by using MDD- and minimal
      residual disease (MRD)- based risk-adapted therapy.

      The Secondary Objectives of this study are:

        -  To determine event-free and overall survival

        -  Investigate the relationship between Day 8 MRD and MDD results and EFS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENT PLAN

      Treatment will consist of 3 main phases: remission induction, consolidation [only for
      patients with any central nervous system (CNS) disease and/or testicular involvement], and
      continuation.

        -  Induction (6-7 weeks).

        -  Consolidation for participants with CNS involvement or those with testicular disease
           only (10 weeks).

        -  Reintensification - Participants with residual disease any time after induction therapy
           may receive 1-2 cycles of re-intensification therapy and may proceed to allogeneic stem
           cell transplant if suitable donor is available.

        -  Continuation Therapy (98-120 weeks).

        -  Intrathecal Chemotherapy (days 1 and 15; if needed also on days 8 and 22)

      TREATMENT SCHEME

      T lymphoblastic lymphoma: bone marrow/peripheral blood (BM/PB) involvement (MDD/MRD):
      Diagnosis: less than 1%; Day 8: +/− (Stratum 1)

        -  Induction

             -  Single dose of Cyclophosphamide

             -  Steroid: prednisone

        -  Continuation: 98 weeks

      T lymphoblastic lymphoma: BM/PB involvement (MDD/MRD): Diagnosis: equal to or greater than
      1%; Day 8: − (Stratum 2)

        -  Induction

             -  Fractionated Cyclophosphamide

             -  Steroid: prednisone

        -  Continuation : 98 weeks

      T lymphoblastic lymphoma: BM/PB involvement (MDD/MRD): Diagnosis: equal to or greater than
      1%; Day 8: + (Stratum 3)

        -  Induction

             -  Fractionated Cyclophosphamide

             -  Steroid: prednisone and dexamethasone

        -  Continuation: 120 weeks

      B lymphoblastic lymphoma: Stage I-III (Stratum 1)

        -  Induction

             -  Single dose of Cyclophosphamide

             -  Steroid: prednisone

        -  Continuation: 98 weeks

      B lymphoblastic lymphoma: Stage IV or testicular (Stratum 2)

        -  Induction

             -  Fractionated Cyclophosphamide

             -  Steroid: prednisone

        -  Continuation: 98 weeks

      Patients with CNS or testicular involvement will receive Consolidation therapy prior to
      continuation therapy and receive extended maintenance therapy (120 weeks).

      Any patient with detectable disease (MRD, bone marrow or biopsy of residual mass) at the end
      of induction may be considered for reintensification and/or hematopoietic stem cell
      transplantation (HSCT).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS).</measure>
    <time_frame>Two years post therapy.</time_frame>
    <description>Kaplan-Meier survival curve estimate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS).</measure>
    <time_frame>Two years post therapy.</time_frame>
    <description>Kaplan-Meier survival curve estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of lymphoblastic cells in bone marrow at diagnosis (MDD) and at day 8 of therapy (MRD).</measure>
    <time_frame>Two years post day 8.</time_frame>
    <description>Cox regression modeling of EFS with MRD and MDD as explanatory variables.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo treatment as described in the intervention section. Interventions include:
Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine
Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine
Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine
Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide
All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given orally (PO).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given intravenously (IV).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Oncovin®</other_name>
    <other_name>Vincristine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Daunomycin</other_name>
    <other_name>Cerubidine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-asparaginase</intervention_name>
    <description>Given intramuscularly (IM) or IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Pegaspargase</other_name>
    <other_name>Oncaspar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinia asparaginase</intervention_name>
    <description>Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Erwinase®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Adriamycin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV or IT.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Given PO.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Purine antimetabolite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cl-F-Ara-A</other_name>
    <other_name>CAFdA</other_name>
    <other_name>2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine</other_name>
    <other_name>Clofarex</other_name>
    <other_name>Clolar^TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV or IT.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Hihg-dose methotrexate (HD-MTX)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Decadron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Given IT.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cortef®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>Vepesid®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have &lt;25% tumor
             cells in bone marrow by morphology)

          2. Age ≤ 21 years

          3. Limited prior therapy, including systemic glucocorticoids for 1 week or less, 1 dose
             of vincristine, emergency radiation therapy to the mediastinum, and 1 dose of IT
             chemotherapy. Other circumstances must be cleared by PI or co-PI.

          4. Written, informed consent and assent following guidelines of the Institutional Review
             Board, National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office
             of Human Research Protections (OHRP).

        Exclusion Criteria:

          1. Participants with prior therapy, other than therapy specified in 3 above.

          2. Participants who are pregnant or lactating.

          3. Inability or unwillingness of research participant or legal guardian/representative to
             give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroto Inaba, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antimetabolites</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

